WO2000066593A3 - Neue spirocyclische verbindungen, verfahren zu deren herstellung und deren verwendung zur behandlung hyperproliferativer erkrankungen - Google Patents

Neue spirocyclische verbindungen, verfahren zu deren herstellung und deren verwendung zur behandlung hyperproliferativer erkrankungen Download PDF

Info

Publication number
WO2000066593A3
WO2000066593A3 PCT/EP2000/003915 EP0003915W WO0066593A3 WO 2000066593 A3 WO2000066593 A3 WO 2000066593A3 EP 0003915 W EP0003915 W EP 0003915W WO 0066593 A3 WO0066593 A3 WO 0066593A3
Authority
WO
WIPO (PCT)
Prior art keywords
hyperproliferative diseases
spirocyclic compounds
production
novel
compounds
Prior art date
Application number
PCT/EP2000/003915
Other languages
English (en)
French (fr)
Other versions
WO2000066593A2 (de
Inventor
Guenter Neef
Harry Vierhufe
Arwed Cleve
Original Assignee
Schering Ag
Guenter Neef
Harry Vierhufe
Arwed Cleve
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag, Guenter Neef, Harry Vierhufe, Arwed Cleve filed Critical Schering Ag
Priority to AU45600/00A priority Critical patent/AU4560000A/en
Publication of WO2000066593A2 publication Critical patent/WO2000066593A2/de
Publication of WO2000066593A3 publication Critical patent/WO2000066593A3/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Die Erfindung betrifft neue spirocyclische Verbindungen der allgemeinen Formel (I), in der X, Y gleich oder verschieden voneinander sind und H, C1-C20-Alkyl, C1-C20-Alkenyl, Aryl, Heteroaryl, CH2OR, CH2SR, CH2Hal, CH2CN, CH2N3, CH2N(R)2, CHO, CH=NOR, CN, COOR, CON(R)2 bedeuten, wobei R ein geradkettiger oder verzweigter Alkyl- oder Acylrest mit bis zu 15 C-Atomen ist, sowie deren optisch aktive Formen, Epimere und physiologisch verträgliche Salze, die zur Behandlung hyperproliferativer Erkrankungen Verwendung finden können.
PCT/EP2000/003915 1999-05-03 2000-05-03 Neue spirocyclische verbindungen, verfahren zu deren herstellung und deren verwendung zur behandlung hyperproliferativer erkrankungen WO2000066593A2 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU45600/00A AU4560000A (en) 1999-05-03 2000-05-03 Novel spirocyclic compounds, method for the production thereof and their use fortreating hyperproliferative diseases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19921101.9 1999-05-03
DE19921101A DE19921101A1 (de) 1999-05-03 1999-05-03 Neue spirocyclische Verbindungen, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung hyperproliferativer Erkrankungen

Publications (2)

Publication Number Publication Date
WO2000066593A2 WO2000066593A2 (de) 2000-11-09
WO2000066593A3 true WO2000066593A3 (de) 2001-05-31

Family

ID=7907317

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/003915 WO2000066593A2 (de) 1999-05-03 2000-05-03 Neue spirocyclische verbindungen, verfahren zu deren herstellung und deren verwendung zur behandlung hyperproliferativer erkrankungen

Country Status (3)

Country Link
AU (1) AU4560000A (de)
DE (1) DE19921101A1 (de)
WO (1) WO2000066593A2 (de)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997033887A1 (en) * 1996-03-15 1997-09-18 Du Pont Pharmaceuticals Company Spirocycle integrin inhibitors
US5760029A (en) * 1996-03-15 1998-06-02 The Dupont Merck Pharmaceutical Company Spirocycle integrin inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997033887A1 (en) * 1996-03-15 1997-09-18 Du Pont Pharmaceuticals Company Spirocycle integrin inhibitors
US5760029A (en) * 1996-03-15 1998-06-02 The Dupont Merck Pharmaceutical Company Spirocycle integrin inhibitors

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BEIL W ET AL: "Enantiopure Building Blocks for Marine Natural Products via Differentiation of Enantiotopic Groups", TETRAHEDRON,NL,ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, vol. 54, no. 26, 25 June 1998 (1998-06-25), pages 7273 - 7292, XP004132264, ISSN: 0040-4020 *
MCKILLOP A ET AL: "THE TOTAL SYNTHESIS OF THE DIEPOXYCYCLOHEXANONE ANTIBIOTIC ARANOROSIN AND NOVEL SYNTHETIC ANALOGUES", JOURNAL OF THE CHEMICAL SOCIETY, PERKIN TRANSACTIONS 1,GB,CHEMICAL SOCIETY. LETCHWORTH, vol. 12, 21 June 1996 (1996-06-21), pages 1385 - 1392, XP002052632, ISSN: 1470-4358 *
WIPF P ET AL: "TOTAL SYNTHESIS AND STRUCTURE ASSIGNMENT OF THE ANTITUMOR ANTIBIOTIC ARANOROSIN", JOURNAL OF ORGANIC CHEMISTRY,US,AMERICAN CHEMICAL SOCIETY. EASTON, vol. 58, no. 25, 1993, pages 7195 - 7203, XP002052631, ISSN: 0022-3263 *

Also Published As

Publication number Publication date
AU4560000A (en) 2000-11-17
WO2000066593A2 (de) 2000-11-09
DE19921101A1 (de) 2000-11-16

Similar Documents

Publication Publication Date Title
WO2001078711A3 (en) Pde-v inhibitors for treatment of parkinson's disease
NZ511673A (en) Carboxylic acids and carboxylic acid isosteres of N- heterocyclic compounds
NO170280C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive sulfamatderivater
NZ325559A (en) Metalloproteinase inhibitors, pharmaceutical compoMetalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical usitions containing them and their pharmaceutical uses, and methods and intermediates useful for theises, and methods and intermediates useful for their preparation r preparation
DE69113155D1 (de) 17-beta-substituierte-4-aza-5-alpha-androstan-3-one-derivate und verfahren zu ihrer herstellung.
EP0948327A4 (de) Antidiabetische mittel
ATE272398T1 (de) Verwendung von ep4 rezeptorliganden zur behandlung von neuropathischen schmerz
IL100289A0 (en) N-iodopropargyloxycarbonyl amino acid esters and derivatives,their preparation and their use as antimicrobial agents
DE69008142D1 (de) 4-Substituierten Imidazolen zur Senkung des intraokularen Druckes.
EG20726A (en) Process for preparing of galanthamine derivatives as acetylchol inc-sterase inhibitors
BG105015A (en) Carboxylic acids and isosteres of carboxylic acids of n-heterocyclic compounds
ATE200622T1 (de) Verwendung von hydantoin-derivaten zur herstellung eines medikaments zur behandlung von krankheiten in zusammenhang mit aktivem sauestoff und freien radikalen
HUT57716A (en) Process for producing sulfonylamino-substituted bicyclic hydroxame acid derivatives and pharmaceutical compositions comprising such compounds
WO2000066593A3 (de) Neue spirocyclische verbindungen, verfahren zu deren herstellung und deren verwendung zur behandlung hyperproliferativer erkrankungen
WO1993004059A1 (en) 4-acylaminoimidazole derivative
BG106846A (en) Novel heteroaryl derivatives, their preparation and use
DE69527854D1 (de) Derivate substituierter amidinonaphthylester
DE69827706D1 (de) 5-(Heteroaryl)alkyl)-3-oxo-pyrido(1,2-a)benzimidazol-4-carboxamid (PBI) Derivate zur Behandlung von Störungen des zentralen Nervensystems
WO2000008006A3 (en) Piperidine and piperazine derivatives, process for their preparation and pharmaceutical compounds containing them
WO2001035938A3 (de) Pharmakologisch aktive tetrahydrothiopyran-4-ol-derivate, verfahren zu ihrer herstellung und verwendung
EP0461264A4 (en) Ethynylphenyl derivative, production thereof, and remedy for diseases of circulatory organs containing the same as active ingredient
EP0370974A3 (de) Verfahren zur Herstellung von heterocyclischen Derivaten

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

NENP Non-entry into the national phase

Ref country code: JP